Cyclopharm (ASX:CYC) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CYC Cyclopharm Ltd ASX:CYC
39 GF Score
Price A$0.59
GF Value A$0.82
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Cyclopharm 3-Month Share Buyback Ratio?

Cyclopharm ASX:CYC -1.68% 39 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 39/100 and a GF Value™ of A$0.82 (Modestly Undervalued). The stock has 7 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

ASX:CYC
39GF Score
Cyclopharm Ltd ASX:CYC
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Cyclopharm (ASX:CYC) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Cyclopharm and its competitors.
Is Cyclopharm's 3-Month Share Buyback Ratio too high?
Cyclopharm's current 3-Month Share Buyback Ratio is 0.00. Overall, Cyclopharm has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's 3-Month Share Buyback Ratio compare to MCK and COR?
Cyclopharm's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Distribution company?
A good 3-Month Share Buyback Ratio depends on the Medical Distribution industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Cyclopharm and its competitors. Cyclopharm's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.82, compared to a current price of A$0.59 — trading 28.7% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Cyclopharm's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.59 is trading 28.7% below its estimated GF Value™ of A$0.82. GuruFocus considers Cyclopharm to be Modestly Undervalued.

Key valuation signals for ASX:CYC:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: A$0.82 vs. price of A$0.59 (28.7% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
39GF Score

Get the complete analysis for ASX:CYC

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.59
Price
A$0.82
GF Value